Retracted: MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2)

Med Sci Monit. 2024 Oct 1:30:e946684. doi: 10.12659/MSM.946684.

Abstract

The Editors of Medical Science Monitor wish to inform you that the above manuscript has been retracted from publication due to concerns with the credibility and originality of the study, the manuscript content, and the Figure images. Reference: Na Li, Mei Han, Ning Zhou, Yong Tang, Xu-Shan Tang. MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit, 2018; 24: CLR5990-5972. DOI: 10.12659/MSM.909458.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Proliferation / genetics
  • Drug Resistance, Neoplasm / genetics
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Receptor, ErbB-2* / genetics
  • Receptor, ErbB-2* / metabolism
  • Signal Transduction* / drug effects
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / metabolism
  • TOR Serine-Threonine Kinases* / metabolism

Substances

  • MicroRNAs
  • TOR Serine-Threonine Kinases
  • Receptor, ErbB-2
  • MTOR protein, human
  • ERBB2 protein, human
  • Antineoplastic Agents
  • MIRN495 microRNA, human